Tarantini G, et al. - This study analyzed data from articles comparing elderly and non-elderly patients with acute coronary syndromes (ACS) in terms of ischemic and bleeding events following treatment with potent P2Y12 inhibitors or clopidogrel. Findings demonstrated that the influence of more potent P2Y12 inhibitors versus clopidogrel on efficacy and safety endpoints was consistent in elderly and younger patients. This study advocated that only because of advanced age, potent P2Y12 inhibitors should not be withheld from eligible patients.